<DOC>
	<DOCNO>NCT02899169</DOCNO>
	<brief_summary>The investigator design multicenter randomize control trial prove RIF plus ATRA possibly superior ATO plus ATRA consolidation maintenance treatment patient non-high-risk APL .</brief_summary>
	<brief_title>Treatment Non-high-risk Acute Promyelocytic Leukemia ( APL ) With Realgar-Indigo Naturalis Formula ( RIF )</brief_title>
	<detailed_description>Acute promyelocytic leukemia ( APL ) unique subtype acute myeloid leukemia ( AML ) account 10-15 % acute myeloid leukemia . It characterize PML-RARA fusion gene generate ( 15 ; 17 ) ( q22 ; q21 ) chromosomal translocation . The application ATRA ATO , make APL highly fatal highly curable . APL0406 study prove ATRA plus arsenic trioxide least inferior may superior ATRA plus chemotherapy treatment patient non-high-risk APL . Now , arsenic trioxide already become base regimen target first-line treatment without chemotherapy . A study show oral RIF plus ATRA inferior intravenous ATO plus ATRA maintenance treatment APL . The investigator design multicenter randomize control trial prove RIF plus ATRA possibly superior ATO plus ATRA consolidation maintenance treatment patient non-high-risk APL . Application oral RIF decrease total hospitalization day .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>age 14 70 year Newly diagnose APL ( 15 ; 17 ) ( q22 ; q12 ) Before treatment Peripheral blood white blood cell count＜40×109/L Patients complete entire treatment process Patients family sign write informed consent Be allergic drug ingredient , supplementary material allergic constitution person Cardiac insufficiency , renal insufficiency , significant arrhythmia , EKG abnormalities important organ dysfunction Combined malignant tumor Pregnant lactate woman Participants drug trial last 3 month Suffering mental illness circumstance unable carry plan Other patient suitable study</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Acute promyelocytic leukemia</keyword>
	<keyword>Realgar-Indigo Naturalis Formula</keyword>
	<keyword>All-trans Retinoic Acid</keyword>
</DOC>